Erlotinib Plus WBRT Effective for NSCLC Brain Metastases
The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Radiation Therapy | Tarceva